Clinical Trial

Additional Prognostic Value of Tumor Grade Beyond the 21-gene Recurrence Score

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 30, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
To evaluated the prognostic significance of tumor grade in patients with node-negative, hormone receptor-positive, and human epidermal growth factor receptor 2-negative breast cancers treated according to RS-guided strategies.
Trial Details
NCT Number NCT07093775
Lead Sponsor Gangnam Severance Hospital
Conditions Breast Cancer, Tumor Grade
Enrollment 4,000 participants
Start Date 2025-07
Primary Completion 2025-12 (estimated)
Study Completion 2026-03 (estimated)
Updated on ClinicalTrials.gov 2025-07-30